KalVista Pharmaceuticals Inc (NASDAQ: KALV) kicked off on Friday, up 9.01% from the previous trading day, before settling in for the closing price of $10.54. Over the past 52 weeks, KALV has traded in a range of $7.30-$15.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -24.26% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -3.28%. With a float of $38.56 million, this company’s outstanding shares have now reached $49.49 million.
In an organization with 150 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 22.44%, while institutional ownership is 89.08%. The most recent insider transaction that took place on Apr 09 ’25, was worth 235,500. In this transaction 10% Owner of this company bought 25,000 shares at a rate of $9.42, taking the stock ownership to the 5,303,985 shares. Before that another transaction happened on Mar 07 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 6,669 for $11.97, making the entire transaction worth $79,828. This insider now owns 287,811 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.85% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Take a look at KalVista Pharmaceuticals Inc’s (KALV) current performance indicators. Last quarter, stock had a quick ratio of 10.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -2.97 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Let’s dig in a bit further. During the last 5-days, its volume was 0.88 million. That was better than the volume of 0.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.98%. Additionally, its Average True Range was 0.91.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 74.82%, which indicates a significant increase from 67.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.35% in the past 14 days, which was higher than the 58.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.01, while its 200-day Moving Average is $11.07. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $11.98. Second resistance stands at $12.46. The third major resistance level sits at $13.25. If the price goes on to break the first support level at $10.71, it is likely to go to the next support level at $9.92. The third support level lies at $9.44 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
The company with the Market Capitalisation of 571.28 million has total of 49,716K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -126,640 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -48,510 K.
